TNSN88081A1 - 1,4-dihydropyridines, leur procede de preparation et leur application comme medicaments - Google Patents

1,4-dihydropyridines, leur procede de preparation et leur application comme medicaments

Info

Publication number
TNSN88081A1
TNSN88081A1 TNTNSN88081A TNSN88081A TNSN88081A1 TN SN88081 A1 TNSN88081 A1 TN SN88081A1 TN TNSN88081 A TNTNSN88081 A TN TNSN88081A TN SN88081 A TNSN88081 A TN SN88081A TN SN88081 A1 TNSN88081 A1 TN SN88081A1
Authority
TN
Tunisia
Prior art keywords
dihydropyridines
medicaments
application
preparation process
substituted
Prior art date
Application number
TNTNSN88081A
Other languages
English (en)
French (fr)
Inventor
Fernandez Torija Carlos
Alvaro Galiano Ramos Joaquin
Original Assignee
Delagrange Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delagrange Lab filed Critical Delagrange Lab
Publication of TNSN88081A1 publication Critical patent/TNSN88081A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
TNTNSN88081A 1987-08-03 1988-08-02 1,4-dihydropyridines, leur procede de preparation et leur application comme medicaments TNSN88081A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP87401799A EP0302980B1 (fr) 1987-08-03 1987-08-03 1,4-Dihydropyridines, leur procédé de préparation et leur application comme médicaments

Publications (1)

Publication Number Publication Date
TNSN88081A1 true TNSN88081A1 (fr) 1990-07-10

Family

ID=8198243

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN88081A TNSN88081A1 (fr) 1987-08-03 1988-08-02 1,4-dihydropyridines, leur procede de preparation et leur application comme medicaments

Country Status (34)

Country Link
US (1) US4952592A (en:Method)
EP (1) EP0302980B1 (en:Method)
JP (1) JPH0733383B2 (en:Method)
KR (1) KR960001724B1 (en:Method)
CN (1) CN1038587C (en:Method)
AT (1) ATE61588T1 (en:Method)
BE (1) BE1001055A4 (en:Method)
CA (2) CA1306261C (en:Method)
CH (1) CH675999A5 (en:Method)
CZ (1) CZ282077B6 (en:Method)
DD (1) DD282008A5 (en:Method)
DE (2) DE3768658D1 (en:Method)
DK (1) DK430288A (en:Method)
ES (1) ES2007543A6 (en:Method)
FI (1) FI91406C (en:Method)
GB (1) GB2208861B (en:Method)
GR (2) GR880100507A (en:Method)
HU (1) HU204523B (en:Method)
IE (1) IE60358B1 (en:Method)
IL (1) IL87321A (en:Method)
IN (1) IN167550B (en:Method)
IS (1) IS1549B (en:Method)
IT (1) IT1235013B (en:Method)
LU (1) LU87297A1 (en:Method)
MA (1) MA21344A1 (en:Method)
NO (1) NO170934C (en:Method)
NZ (1) NZ225661A (en:Method)
PH (1) PH25645A (en:Method)
PT (1) PT88173B (en:Method)
RU (1) RU2036922C1 (en:Method)
SK (1) SK541388A3 (en:Method)
TN (1) TNSN88081A1 (en:Method)
YU (1) YU46547B (en:Method)
ZA (1) ZA885684B (en:Method)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242933A (en) * 1990-07-10 1993-09-07 Adir Et Compagnie Piperidine, tetrahydropyridine and pyrrolidine compounds
US5942516A (en) * 1995-08-02 1999-08-24 Elliott; John Duncan Endothelin receptor antagonists
RU2168987C2 (ru) * 1997-04-15 2001-06-20 Санкт-Петербургская Государственная Химико-Фармацевтическая Академия Гипотензивное средство
RU2155036C2 (ru) * 1998-11-11 2000-08-27 Азад Зияд Оглы Абышев Средство для лечения ишемической болезни сердца
IT1304513B1 (it) * 1998-12-30 2001-03-19 Endura Spa Processo per la sintesi di 5-(alfa-idrossialchil)benzo(1,3)diossoli.
CZ301790B6 (cs) * 2000-04-11 2010-06-23 Sankyo Company Limited Farmaceutický prípravek obsahující blokátor vápníku
RU2187303C2 (ru) * 2000-10-12 2002-08-20 Азад Зияд Оглы Абышев Способ получения таблеток диуманкала - forte по 0,01 г
WO2004017964A1 (en) 2002-08-19 2004-03-04 Pfizer Products Inc. Combination therapy for hyperproliferative diseases
MX2007000979A (es) * 2004-07-26 2007-07-11 Cotherix Inc Tratamiento de la hipertension pulmonar por iloprost inhalado con una formulacion microparticulada.
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
EP2351569B1 (en) 2005-10-26 2012-08-22 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
WO2007050783A2 (en) 2005-10-26 2007-05-03 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
TW200806648A (en) * 2005-11-29 2008-02-01 Sankyo Co Acid addition salts of dihydropyridine derivatives
TW200736245A (en) * 2005-11-29 2007-10-01 Sankyo Co Acid addition salts of optically active dihydropyridine derivatives
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
ES2382009T3 (es) 2006-12-01 2012-06-04 Bristol-Myers Squibb Company Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares
WO2012037665A1 (en) 2010-09-24 2012-03-29 Oral Delivery Technology Ltd. Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions
CA2909442A1 (en) 2013-04-17 2014-10-23 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
US11248001B2 (en) 2019-01-18 2022-02-15 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3441648A (en) * 1967-02-07 1969-04-29 Smithkline Corp Compositions and methods for lowering blood pressure with 1,4-dihydropyridines
US4031104A (en) * 1972-04-18 1977-06-21 Bayer Aktiengesellschaft 1,4-Dihydropyridine carboxylic acid esters
JPS5978186A (ja) * 1982-10-27 1984-05-04 Yoshitomi Pharmaceut Ind Ltd １，４−ジヒドロピリジン−３，５−ジカルボン酸エステル誘導体
IE57810B1 (en) * 1984-03-27 1993-04-21 Delagrange Lab 1,4-dihydropyridine derivatives,their preparation and their use
ES8507495A1 (es) * 1984-03-27 1985-09-01 Inst Investigacion Desarrollo Un procedimiento para la preparacion de nuevas 1,4-dihidropirinas-4-(polioxialquilfenil)-sustituidas
JPH068294B2 (ja) * 1985-02-26 1994-02-02 富山化学工業株式会社 新規な１，４−ジヒドロピリジン誘導体およびその塩
EP0174131A3 (en) * 1984-09-01 1989-06-07 FISONS plc Dihydropyridines, processes and intermediates for their production, and pharmaceutical formulations containing them
JPH01207267A (ja) * 1987-03-05 1989-08-21 Yamanouchi Pharmaceut Co Ltd ピリジン誘導体及び該化合物を含有する肝疾患治療剤

Also Published As

Publication number Publication date
AU606441B2 (en) 1991-02-07
NO170934B (no) 1992-09-21
RU2036922C1 (ru) 1995-06-09
EP0302980B1 (fr) 1991-03-13
DD282008A5 (de) 1990-08-29
ES2007543A6 (es) 1989-06-16
CZ282077B6 (cs) 1997-05-14
IS3378A7 (is) 1989-02-04
PH25645A (en) 1991-08-21
DK430288D0 (da) 1988-08-02
GB2208861B (en) 1991-07-17
EP0302980A1 (fr) 1989-02-15
IT1235013B (it) 1992-06-16
SK278775B6 (sk) 1998-02-04
JPH0733383B2 (ja) 1995-04-12
SK541388A3 (en) 1998-02-04
KR890003743A (ko) 1989-04-17
IL87321A (en) 1993-04-04
ATE61588T1 (de) 1991-03-15
IN167550B (en:Method) 1990-11-10
DE3768658D1 (de) 1991-04-18
BE1001055A4 (fr) 1989-06-20
GB2208861A (en) 1989-04-19
PT88173A (pt) 1989-06-30
CZ541388A3 (en) 1997-01-15
YU46547B (sh) 1993-11-16
CH675999A5 (en) 1990-11-30
ZA885684B (en) 1989-04-26
FI91406B (fi) 1994-03-15
HUT54142A (en) 1991-01-28
FI91406C (fi) 1994-06-27
DE3825962A1 (de) 1989-02-16
JPH01294675A (ja) 1989-11-28
KR960001724B1 (ko) 1996-02-03
CA1306262C (fr) 1992-08-11
NZ225661A (en) 1990-08-28
IS1549B (is) 1994-06-08
MA21344A1 (fr) 1989-04-01
AU2033088A (en) 1989-02-09
CN1038587C (zh) 1998-06-03
HU204523B (en) 1992-01-28
NO170934C (no) 1992-12-30
DK430288A (da) 1989-02-03
NO883406L (no) 1989-02-06
GB8818356D0 (en) 1988-09-07
GR3001984T3 (en) 1992-11-23
PT88173B (pt) 1995-03-01
FI883603A7 (fi) 1989-02-04
IL87321A0 (en) 1989-01-31
US4952592A (en) 1990-08-28
NO883406D0 (no) 1988-08-01
LU87297A1 (fr) 1989-02-02
CA1306261C (fr) 1992-08-11
GR880100507A (el) 1989-05-25
YU147088A (en) 1990-04-30
IT8848259A0 (it) 1988-08-02
IE60358B1 (en) 1994-06-29
IE882364L (en) 1989-02-03
CN1031531A (zh) 1989-03-08
FI883603A0 (fi) 1988-08-01

Similar Documents

Publication Publication Date Title
TNSN88081A1 (fr) 1,4-dihydropyridines, leur procede de preparation et leur application comme medicaments
EP0138441A3 (en) Anticonvulsant sulfamate derivatives
HUP9600448A2 (hu) Naftilvegyületek, e vegyületeket tartalmazó gyógyszerkészítmények, eljárás előállításukra, intermedierjeik és alkalmazásuk
BE900345A (fr) Composition pharmaceutique ophtalmiques a base d'un derive d'acide phenylacetique.
DE3477488D1 (en) Polymethoxybenzyl piperazine derivatives, processes for their preparation and pharmaceutical compositions containing said derivatives
ES8504682A1 (es) Un procedimiento para la preparacion de compuestos nitro alifaticos
EP0186023A3 (en) Biliary acid derivatives, process for their preparation and pharmaceutical compositions containing them
IL93989A0 (en) Pharmaceutical compositions comprising heteroaryl-3-oxo-propanenitrile derivatives useful in the treatment of rheumatoid arthritis and other autoimmune diseases
TNSN99114A1 (fr) Oxo-thia-azabicyclooctenes, preparations pharmaceutiques les contenant, et leur utilisation pour le traitement et la prophylaxie de maladies infectieuses
EP0123962A3 (en) Novel benzimidazole derivative, process for the preparation thereof and pharmaceutical composition
IL99468A (en) (3s, 4s)-delta- 6-tetrahydrocannabinol- 7-oic acids and derivatives thereof, processes for their preparation and pharmaceutical compositions containing them
DE3374005D1 (en) 1-methyl-5-nitro-imidazoline derivatives and therapeutic compositions which contain them as active principle
GR3007219T3 (en:Method)
ES8100249A1 (es) Un metodo para la preparacion de un compuesto de acido hi- droxamico
RU94042230A (ru) Производные 1,3,4-оксадиазол-2-(3н)-она, их приготовление и применение в терапии
FR2451363A1 (fr) (1,1-biphenyl-2-yl)-propyl- et butylamines, leur preparation et leur utilisation therapeutique
TNSN86099A1 (fr) Nouveaux benzamides, leur procede de preparation et leur application dans le domaine therapeutique
HUT54688A (en) Process for producing compounds utilizable for treating ulcus and pharmaceutical compositions containing them as active components
ATE56438T1 (de) 1-(cyclohexyl>-3,4-di-(hydro>isochinolinderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
CA2011143A1 (en) Pyridinecarboxylic acid amide derivatives and pharmaceutical compositions comprising same
FR2626470B1 (fr) Depresseur de l'inhibiteur de l'(alpha)2-plasmine
TNSN88083A1 (fr) Procede de preparation de nouveaux derives de thieno-imidazole substitues
DK644487A (da) Farmaceutisk praeparat indeholdende en 2-oxo-imidazolidinforbindelse
DE3561620D1 (en) Nitrosoureas compounds preparation thereof and utilization thereof in anticancerous chemiotherapy
ES8105734A1 (es) Un procedimiento para la preparacion de agentes antibacterianos beta-lactanicos.